Cook Medical launches new products for treating peripheral arterial disease

In a tour de force of new product development and introduction, Cook Medical is introducing six new products in parallel to provide better treatment options to the physicians treating the 27 million people worldwide afflicted with some form of peripheral arterial disease (PAD) and other diseases of the circulatory system.

These products include new microwires, stents and angioplasty balloons that are integral to Cook’s advanced Leg Therapy Program, the industry’s broadest line of products engineered specifically to address the dynamic circulation of the iliac, femoral, popliteal and infrapopliteal vascular systems. In addition, Cook will introduce a new thoracic aneurysm endograft and a sophisticated new delivery and retrieval system for Cook’s inferior vena cava filters for pulmonary embolism prevention to physicians attending VIVA 2009.

“This is a significant day for patients suffering from PAD, as Cook proudly rolls out an integrated line of minimally invasive products designed specifically for treating PAD,” said Rob Lyles, vice president and global leader of Cook Medical’s peripheral intervention division. “People tend to associate leg conditions exclusively with injury, and fail to recognize the importance of maintaining the overall health of the legs until it’s too late. By introducing these six products to the vascular medicine and interventional communities, we are giving vascular interventionalists six tools to improve their patient outcomes and deliver actionable solutions to those who need them most.”

SOURCE Cook Medical

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation